Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950566 | 0.84 | HDAC3 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4224827 | 0.83 | PTPN1 (0.58) | GSK3BHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11392836 | 0.82 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4261541 | 0.81 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11321458 | 0.81 | HSD17B3 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5843687 | 0.81 | ALDH1A1 (0.59) | GSK3BHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4261547 | 0.81 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL774179 | 0.80 | GSK3B (0.61) | GSK3BHDAC1HDAC6PTPN1MAPT | |
| SCHEMBL10001068 | 0.80 | GSK3B (0.61) | GSK3BHDAC1HDAC6PTPN1MAPT | |
| SCHEMBL10001066 | 0.80 | GSK3B (0.61) | GSK3BHDAC1HDAC6PTPN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233864-B1 | COMPOSITION COMPRISING AN INDOLIZINE DERIVATIVE AND A CYCLIC DINUCLEOTIDE AS ACTIVE AGENTS | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4233864-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | Ajou University Industry-Academic Cooperation Foundation (KR) | 2023-08-30 | — | — | EP | disclosed |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022086260-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | 아주대학교산학협력단 | 2022-04-28 | — | — | WO | disclosed |
| WO-2022065938-A1 | COMPOUND FOR AGGREGATION-INDUCED EMISSION, COMPOSITION FOR CELL IMAGING USING SAME, AND USE AS CELL-IMAGING CONTRAST AGENT | 아주대학교산학협력단 | 2022-03-31 | — | — | WO | disclosed |
| CN-110003231-B | 1, 1-spironorbornane-pyrano [4, 3-b ] chromone compound and preparation method and application thereof | 遵义医科大学 | 2021-08-10 | — | — | CN | disclosed |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3502109-A1 | TRIAZOLE-PHENYL-THIAZOLE HETEROCYCLES AS INNOVATIVE INHIBITORS OF TRYPANOTHIONE REDUCTASE AND THEIR USE AS LEISHMANICIDES | Consejo Superior De Investigaciones Científicas (ES) | 2019-06-26 | — | — | EP | disclosed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | disclosed |
| US-20020151676-A1 | Streptogramin derivatives, preparation method and compositions containing same | AVENTIS PHARMA S.A. (FR) | 2002-10-17 | — | — | US | disclosed |
| EP-1054886-B1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | disclosed |
| EP-1213282-A1 | Substituted imidazolium salts and their use for the inhibition of protein ageing. | ALTEON Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| CN-1337961-A | Heteroaryl amidines, methyl amidiues and guanidines as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-02-27 | — | — | CN | disclosed |
| CN-1290270-A | Streptogramin derivatives, preparation method and compositions containing them | AWENTIS PHARMACEUTICS S A (FR) | 2001-04-04 | — | — | CN | disclosed |
| EP-0920418-A1 | SUBSTITUTED IMIDAZOLIUM SALTS AND THEIR USE FOR THE INHIBITION OF PROTEIN AGEING | ALTEON, INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1997042175-A1 | SUBSTITUTED IMIDAZOLIUM SALTS AND THEIR USE FOR THE INHIBITION OF PROTEIN AGEING | ALTEON INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| US-4143148-A | ANTI-ULCER THIAZOLINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HTR3D, PTGDR2, PTGIR | GSK3B 4244/4885HDAC3 1637/4885HDAC4 2644/4885 |
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | STING1, IRF3, IFNG | GSK3B 1749/4885HDAC3 4640/4885HDAC4 3383/4885 |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | GSK3B 1797/4885HDAC3 266/4885HDAC4 131/4885 |
| US-20020151676-A1 | Streptogramin derivatives, preparation method and compositions containing same | MRPL21, RRS1, RRP1B | GSK3B 4623/4885HDAC3 4320/4885HDAC4 4295/4885 |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | TBXA2R, HRH2, CYP4F3 | GSK3B 4628/4885HDAC3 1892/4885HDAC4 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.